Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4636 Comments
1987 Likes
1
Sharida
Registered User
2 hours ago
{协议答案}
👍 175
Reply
2
Alaynna
Influential Reader
5 hours ago
{协议答案}
👍 87
Reply
3
Keneshia
Consistent User
1 day ago
{协议答案}
👍 276
Reply
4
Aaban
Expert Member
1 day ago
{协议答案}
👍 69
Reply
5
Atnhony
Influential Reader
2 days ago
{协议答案}
👍 263
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.